Comparative Pharmacology
Head-to-head clinical analysis: CANDESARTAN CILEXETIL versus TEVETEN HCT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CANDESARTAN CILEXETIL versus TEVETEN HCT.
CANDESARTAN CILEXETIL vs TEVETEN HCT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Candesartan cilexetil is a prodrug that is hydrolyzed to candesartan, an angiotensin II receptor blocker (ARB) that selectively and competitively binds to the angiotensin II type 1 (AT1) receptor, blocking the vasoconstrictor and aldosterone-secreting effects of angiotensin II. This results in decreased peripheral resistance and blood pressure.
TEVETEN HCT combines eprosartan mesylate, an angiotensin II receptor antagonist, and hydrochlorothiazide, a thiazide diuretic. Eprosartan blocks the vasoconstrictor and aldosterone-secreting effects of angiotensin II by selectively antagonizing the AT1 receptor. Hydrochlorothiazide inhibits the sodium-chloride symporter in the distal convoluted tubule, increasing excretion of sodium, chloride, and water, thereby reducing plasma volume.
Oral, 8 mg once daily initially, titrate to 16-32 mg once daily as tolerated; maximum 32 mg/day.
One tablet orally once daily, containing eprosartan 600 mg and hydrochlorothiazide 12.5 mg or 25 mg, with or without food. Maximum dose: eprosartan 600 mg/hydrochlorothiazide 25 mg per day.
None Documented
None Documented
Clinical Note
moderateCandesartan cilexetil + Torasemide
"The risk or severity of hypotension can be increased when Candesartan cilexetil is combined with Torasemide."
Clinical Note
moderateCandesartan cilexetil + Etacrynic acid
"The risk or severity of hypotension can be increased when Candesartan cilexetil is combined with Etacrynic acid."
Clinical Note
moderateCandesartan cilexetil + Furosemide
"The risk or severity of hypotension can be increased when Candesartan cilexetil is combined with Furosemide."
Clinical Note
moderateThe terminal elimination half-life is approximately 9 hours. In clinical practice, this supports once-daily dosing, with steady state achieved within 3–4 days.
Eprosartan: 5-9 hours; Hydrochlorothiazide: 6-15 hours; allows once-daily dosing.
Candesartan is eliminated primarily via the kidneys (approximately 60% of recovered dose) and the feces (approximately 40%) following biliary excretion. Less than 1% is excreted unchanged in urine.
Eprosartan: renal (70% unchanged, 10% as metabolite), biliary/fecal (20%); Hydrochlorothiazide: renal (≥95% unchanged).
Category D/X
Category C
ARB
ARB + Thiazide Diuretic Combination
Candesartan cilexetil + Bumetanide
"The risk or severity of hypotension can be increased when Candesartan cilexetil is combined with Bumetanide."